ArticleFrontiers in public health2022
Survival and risk factors associated with mortality in people living with HIV from 2005 to 2018 in Nanjing, China.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Survival outcomes of older people living with HIV from 2001 to 2020 in Hunan, China: a retrospective cohort study.BMC public health · 2026Article
- Longitudinal trends in mortality and its causes among migrant HIV/AIDS patients undergoing antiretroviral therapy compared to their counterparts: a cohort study, 2016-2022.BMC public health · 2025Article
- Survival analysis of PLWH on antiretroviral therapy in Henan Province from 2004 to 2024.Scientific reports · 2025Article
- Effect of antiretroviral therapy on the mortality of HIV-1 infection long-term non-progressors: a cohort study.BMC infectious diseases · 2025Article
- Non-linear association between CD4+ T-cell counts and mortality risk in people living with HIV: evidence from a 10-year cohort study.Frontiers in medicine · 2025Article
- Antiretroviral treatment outcomes and survival pattern of people living with HIV in Bauchi State, Nigeria.PloS one · 2025Article
- Survival analysis and factors influencing survival time of adult HIV/AIDS patients receiving antiretroviral therapy from 2012 to 2022 in Chongqing, China: a retrospective cohort study.Frontiers in public health · 2025Article
- Molecular transmission network analysis of newly diagnosed HIV-1 infections in Nanjing from 2019 to 2021.BMC infectious diseases · 2024Article
- HIV Services Uptake Among People Living with HIV in Jiangsu Province, China: A Cross-Sectional Study.AIDS and behavior · 2024Article
- Survival analysis of PLWHA undergoing combined antiretroviral therapy: exploring long-term prognosis and influencing factors.Frontiers in public health · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although the introduction of antiretroviral therapy (ART) decreased the mortality of people living with Human Immunodeficiency Virus (PLHIV), substantially, hundreds of thousands of people are dying of AIDS each year. The accurate survival patterns and factors related to death among PLHIV were rarely reported. In this study, we evaluated survival status and identified factors associated with death among PLHIV in Nanjing. Methods: We conducted a retrospective analysis of PLHIV followed-up in Nanjing and registered to the national HIV/AIDS comprehensive management information system from 2005 to 2018. We used the life table to calculate the cumulative survival rates. We applied the Kaplan-Meier to calculate median survival times and employed cox hazard proportional regression to analyze the associated factors related to death. Results: The median survival time of PLHIV was 11.8 (95% Conclusion: The AIDS-related mortality among PLHIV in Nanjing was relatively low. A higher risk for AIDS-related deaths were observed among PLHIV who unaccepted ART, whose baseline CD4 cell count was<200 cell/μL, older age, and lower educated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.